Loading company…
Orchestra BioMed develops therapies for hypertension and atherosclerotic artery disease, including BackBeat CNT and Virtue SAB.
Founded in 2017 and based in New Hope, US, Orchestra BioMed, Inc. develops late-stage product candidates, including BackBeat CNT, a bioelectronic treatment for blood pressure, and Virtue SAB, a sirolimus drug-device combination used during balloon angioplasty. Revenue relies on partnerships with medical device companies. The company completed a merger that raised USD 20.00 mn within total funding of USD 110.00 mn, with investors including Health Sciences Acquisitions Corporation 2, Medtronic plc, and RTW Investments. David Hochman is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in